论文部分内容阅读
５２例Ｇｒａｖｅｓ’病（ＧＤ）患者随机分为两组，２６例接受他巴唑（ＭＭＩ）治疗，２６例接受ＭＭＩ加心得安治疗。应用酶联免疫吸附法（ＥＬＩＳＡ），测定了未治疗（第０周）、部分缓解（第２周）和缓解组（第６周）患者及２０例健康对照者血清可溶性ｇｐ１３０（ｓｇｐ１３０）水平。结果表明：①ＭＭＩ和ＭＭＩ加心得安治疗的未治疗组、部分缓解组患者血清ｓｇｐ１３０水平显著高于健康对照组（Ｐ＜０．０１），缓解组与健康对照者血清ｓｇｐ１３０水平无显著差异（Ｐ＞０．０５）；②ＭＭＩ与ＭＭＩ加心得安治疗患者对应组的血清ｓｇｐ１３０水平无差异（分别Ｐ＞０．０５）；③ＧＤ患者血清ｓｇｐ１３０与游离Ｔ３、游离Ｔ４水平呈正相关（分别ｒ＝０．３１８，ｒ＝０．２９７，Ｐ＜０．０５）。提示：ＭＭＩ对ＧＤ患者血清ｓｇｐ１３０的产生具有抑制作用
Fifty-two patients with Graves’ disease (GD) were randomly divided into two groups: 26 received MMI and 26 received MMI plus risperidol. The levels of serum soluble gp130 (sgp130) in untreated (0th week), partial remission (2nd week) and remission group (6th week) and 20 healthy controls were determined by enzyme-linked immunosorbent assay (ELISA) The results showed that: (1) There was no significant difference in serum sgp130 level between remission group and healthy controls (P <0.01), and no significant difference was found between serum sgp130 level of remission group and healthy control group > 0.05). ② There was no difference in serum sgp130 between MI and MMI group (P> 0.05). ③Group sgp130 was positively correlated with free T3 and free T4 level (r = 0 respectively). 318, r = 0.297, P <0.05). Hint: MMI can inhibit the production of sgp130 in GD patients